Search

Sherif Daouti

from Totowa, NJ
Age ~56
Get Report
Also known as:
Sherif Daoutt, Sheif Daviti
Phone and address:
63 Minnisink Rd, Paterson, NJ 07512
(973) 942-5470
Related to:
Merieme Mamo, 58Paul S Desics, 55Fatine MamoFuat Mamo, 62Nexhipe Desics, 53Fationa Mamo, 34Tatiana Vedra, 37Sylvia DautiNegip Daouti, 98
Connected to:
Ibrahim S Daowd, 60Monae H Dapa, 50Dorothy A Dapaah, 47Nelson C Dapar, 30Thomas A Daparma, 73John E Dapcevich, 98Dennis Dapcic, 34Hector B Dapena, 50Jasmin Daphka, 40Gregory P Daphne, 31

Sherif Daouti Phones & Addresses

  • 63 Minnisink Rd, Totowa, NJ 07512 (973) 942-5470
  • Paterson, NJ
  • Fair Lawn, NJ
  • 137 Berkshire Rd, Hasbrouck Heights, NJ 07604
  • 210 Burns Ave, Lodi, NJ 07644 (973) 340-1070
  • Hackensack, NJ

Publications

Us Patents

High Throughput Functional Genomic Screening Methods For Osteoarthritis

View page
US Patent:
20060188885, Aug 24, 2006
Filed:
Apr 16, 2004
Appl. No.:
10/553520
Inventors:
Dale Bodian - Whippany NJ, US
Sherif Daouti - Hasbrouck Heights NJ, US
Chandrika Kumar - Acton MA, US
Brian Latario - Groton MA, US
Joseph Quintavalla - New Providence NJ, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
High-throughput functional screening assays are provided that identify genes and gene products that are associated with the pathogenesis of osteoarthritis (OA) in chondrocytes. In addition, genes and gene products identified by such functional assays are also provided. The genes and gene products provided herein are useful inter alia for diagnosing OA in individuals and as drug targets for identifying drugs to treat OA.

Methods And Compositions Targeting Tyrosine Kinases For The Diagnosis And Treatment Of Osteoarthritis

View page
US Patent:
20070142273, Jun 21, 2007
Filed:
Apr 16, 2004
Appl. No.:
10/553730
Inventors:
Sherif Daouti - Hasbrouck Heights NJ, US
Chandrika Kumar - Acton MA, US
Brian Latario - Groton MA, US
International Classification:
A61K 38/17
C12Q 1/68
G01N 33/567
US Classification:
514012000, 435007200, 435006000
Abstract:
The invention discloses that members of a subfamily of receptor tyrosine kinases comprising TYRO3, Axl, cMer and ligands thereof, such as GAS6 are suitable targets for the development of new therapeutics to treat, prevent or ameliorate OA. The invention also relates to methods to treat and/or ameliorate OA and pharmaceutical compositions therefore comprising modulators with inhibitory effect on the expression or activity of members of this subfamily of receptor tyrosine and related ligands. The invention also relates to a method to identify compounds with therapeutic usefulness to treat OA, comprising identifying compounds that can, e.g., inhibit activity and/or expression of these polypeptides.

Methods For The Treatment Of Osteoarthritis And Compositions Thereof

View page
US Patent:
20060067938, Mar 30, 2006
Filed:
Oct 25, 2002
Appl. No.:
10/491798
Inventors:
Sherif Daouti - Hasbrouck Heights NJ, US
Chanrika Kumar - Maynard MA, US
Brian Latario - Groton MA, US
International Classification:
A61K 31/5377
A61K 39/395
US Classification:
424146100, 514232500
Abstract:
The invention discloses PI3K, PKB, IL-1, and OSM as suitable targets for the development of new therapeutics to treat, prevent or ameliorate osteoarthritis (OA). The invention relates to methods to treat, prevent or ameliorate OA and pharmaceutical compositions therefor comprising substances with inhibitory effects on PI3K and/or PKB enzyme activity and/or gene expression and IL-1 and/or OSM activity or gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat OA, comprising identifying compounds that can effect PI3K and/or PKB activity and/or gene expression and/or IL-1 or OSM activation of PI3K and/or PKB activity and/or gene expression which leads to downregulation of AGG-1 and/or COL-3 and thus prevent, treat or ameliorate OA in vivo.

Bispecific Antibodies Specific For Fap And Dr5, Antibodies Specific For Dr5 And Methods Of Use

View page
US Patent:
20190062453, Feb 28, 2019
Filed:
Mar 6, 2018
Appl. No.:
15/913713
Inventors:
- Schlieren, CH
Sherif Daouti - Totowa NJ, US
Ningping Feng - Richmond Hill, CA
Claudia Ferrara Koller - Zug, CH
Guy Georges - Habach, DE
Sandra Grau-Richards - Birmensdorf, CH
Ralf Hosse - Cham, CH
Christian Klein - Bonstetten, CH
Maximiliane Koenig - Pullach, DE
Joerg Moelleken - Muenchen, DE
Ekkehard Moessner - Kreuzlingen, CH
Huifeng Niu - Scotch Plains NJ, US
Kathryn E. Packman - Newton MA, US
Valeria Runza - Penzberg, DE
Stefan Seeber - Sindelsdorf, DE
Pablo Umana - Wollerau, CH
lnja Waldhauer - Urdorf, CH
Huisheng Wang - Edison NJ, US
Barbara Weiser - Sindelsdorf, DE
Assignee:
Roche Glycart AG - Schlieren
International Classification:
C07K 16/40
C07K 16/28
Abstract:
The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific Antibodies Specific For Fap And Dr5, Antibodies Specific For Dr5 And Methods Of Use

View page
US Patent:
20140370019, Dec 18, 2014
Filed:
Apr 1, 2014
Appl. No.:
14/231933
Inventors:
- Schlieren, CH
Sherif Daouti - Totowa NJ, US
Ningping Feng - Richmond Hill, CA
Claudia Ferrara Koller - Zug, CH
Guy Georges - Habach, DE
Sandra Grau-Richards - Birmensdorf, CH
Ralf Hosse - Cham, CH
Christian Klein - Bonstetten, CH
Maximiliane Koenig - Pullach, DE
Joerg Moelleken - Muenchen, DE
Ekkehard Moessner - Kreuzlingen, CH
Huifeng Niu - Scotch Plains NJ, US
Kathryn E. Packman - Newton MA, US
Valeria Runza - Penzberg, DE
Stefan Seeber - Sindelsdorf, DE
Pablo Umana - Wollerau, CH
Inja Waldhauer - Urdorf, CH
Huisheng Wang - Edison NJ, US
Barbara Weiser - Sindelsdorf, DE
Assignee:
ROCHE GLYCART AG - Schlieren
International Classification:
C07K 16/40
C07K 16/28
US Classification:
4241361, 5303873, 5303891, 4241301, 536 2353, 4353201, 435328, 435 696
Abstract:
The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Control profile
Sherif Daouti from Totowa, NJ, age ~56 Get Report